A reduction of reimbursement tariffs for IVD tests expected in Switzerland

On March 10, 2022, the Associations of Swiss Health Insurance Companies santésuisse announced that the Swiss Federal Department of Home Affairs (FDHA) has confirmed that they would input efforts with the goal of reducing tariffs for laboratory tests (reference), which is a consequence of santésuisse's repeated call for price reductions in the previous years (example). Santésuisse expects the price reduction to be substantial and to enter into force soon

In a February 2021 report, santésuisse showed that the 39 most common laboratory tests in Switzerland cost on average three times as much as in Germany, France, Austria, or the Netherlands. For example (as provided in the letter to the Federal Council), in 2019, the chlamydia test (code 3396.00) cost CHF 95, while in France, Germany, and Austria, the same test, at the same time, was provided for 25.92, CHF 23.65, and CHF 18.11, respectively.

On March 7, 2022, the Federal Councilor announced that interim steps towards the reduction of tariffs for IVD tests would be taken quickly. The focus will be on a percentage reduction of the current tariffs to a set of transitional tariffs. The transitional tariffs will be valid until the completion of the regular reclassification of all items in the List of Analyses (which may take several years) (reference).

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).